Knights of Columbus Asset Advisors LLC Lowers Stock Holdings in Stryker Corporation $SYK

Knights of Columbus Asset Advisors LLC cut its holdings in Stryker Corporation (NYSE:SYK) by 28.5% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,210 shares of the medical technology company’s stock after selling 9,640 shares during the period. Knights of Columbus Asset Advisors LLC’s holdings in Stryker were worth $8,950,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of SYK. Pittenger & Anderson Inc. lifted its holdings in shares of Stryker by 387.8% in the 3rd quarter. Pittenger & Anderson Inc. now owns 14,877 shares of the medical technology company’s stock valued at $5,500,000 after acquiring an additional 11,827 shares during the last quarter. Tandem Investment Advisors Inc. boosted its stake in shares of Stryker by 2.7% during the third quarter. Tandem Investment Advisors Inc. now owns 280,444 shares of the medical technology company’s stock valued at $103,672,000 after purchasing an additional 7,425 shares in the last quarter. Benedict Financial Advisors Inc. purchased a new stake in shares of Stryker during the 3rd quarter worth $2,119,000. SYM FINANCIAL Corp purchased a new stake in shares of Stryker during the third quarter valued at about $522,000. Finally, Patton Albertson Miller Group LLC lifted its position in Stryker by 17.4% during the third quarter. Patton Albertson Miller Group LLC now owns 18,664 shares of the medical technology company’s stock valued at $6,900,000 after acquiring an additional 2,762 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on SYK shares. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Stryker in a research report on Monday, December 22nd. Citizens Jmp upgraded Stryker from a “market perform” rating to an “outperform” rating and set a $440.00 target price on the stock in a research report on Friday, December 19th. Raymond James Financial upgraded shares of Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 target price on the stock in a research report on Tuesday, January 6th. Citigroup lowered their target price on shares of Stryker from $455.00 to $420.00 and set a “buy” rating on the stock in a research note on Thursday, December 11th. Finally, BTIG Research reaffirmed a “buy” rating and set a $410.00 price target on shares of Stryker in a research report on Friday, November 14th. Twelve research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $425.94.

Insider Transactions at Stryker

In other Stryker news, CFO Preston Wendell Wells sold 165 shares of Stryker stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $365.88, for a total value of $60,370.20. Following the completion of the sale, the chief financial officer owned 6,694 shares in the company, valued at $2,449,200.72. The trade was a 2.41% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Ronda E. Stryker sold 276,173 shares of the stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $353.28, for a total value of $97,566,397.44. Following the completion of the transaction, the director directly owned 2,702,108 shares of the company’s stock, valued at $954,600,714.24. This represents a 9.27% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 522,118 shares of company stock worth $185,381,932 over the last quarter. 5.90% of the stock is currently owned by insiders.

Stryker Price Performance

Shares of NYSE SYK opened at $354.39 on Friday. The company has a market cap of $135.52 billion, a PE ratio of 46.57, a P/E/G ratio of 2.29 and a beta of 0.89. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $404.87. The stock has a fifty day moving average price of $359.38 and a 200 day moving average price of $371.95. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.85 and a quick ratio of 1.13.

Stryker (NYSE:SYK) last released its earnings results on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, beating analysts’ consensus estimates of $4.40 by $0.07. The company had revenue of $7.17 billion during the quarter, compared to the consensus estimate of $7.12 billion. Stryker had a return on equity of 24.07% and a net margin of 12.07%.Stryker’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter last year, the company earned $4.01 earnings per share. Sell-side analysts forecast that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Wednesday, December 31st will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, December 31st. This is a positive change from Stryker’s previous quarterly dividend of $0.84. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. Stryker’s payout ratio is currently 46.25%.

Stryker News Roundup

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Quarterly beat — Stryker posted Q4 adjusted EPS $4.47 (vs. $4.40 consensus) and revenue $7.17B, with organic sales up ~11% and adjusted operating margin expanding 100 bps, signaling continued top‑line momentum and operating leverage. Stryker reports 2025 operating results and 2026 outlook
• Positive Sentiment: Raised outlook/supportive commentary — Management now guides 2026 organic net sales growth of 8.0%–9.5% and adjusted EPS $14.90–$15.10 and indicated modestly favorable pricing and FX, prompting firms to keep/confirm Buy ratings. Reuters notes management raised its profit forecast tied to strong capital and implant demand. Stryker raises annual profit forecast on strong sales for medical devices
• Positive Sentiment: Analyst support — Multiple shops (Needham, Piper Sandler and others) reiterated Buy/Overweight ratings after the results, citing sustained double‑digit growth in key MedSurg/Neuro businesses and improved margins. Stryker: Sustained Double-Digit Growth and Operating Leverage Support Buy Rating
• Neutral Sentiment: FY26 EPS range roughly in line with consensus — the $14.90–$15.10 range centers near Street estimates (consensus ~14.96). That calmingly conservative guidance reduces upside surprise potential and helps explain muted share reaction despite the beat.
• Neutral Sentiment: Earnings call / details available — full Q4 earnings call transcript and company presentation provide more color on product momentum, capital demand and margin drivers for investors reviewing catalysts. Stryker Q4 2025 Earnings Call Transcript
• Negative Sentiment: Tariff/regulatory risks flagged — some analysts and the company note potential 2026 tariff headwinds and geopolitical/regulatory risks that could pressure margins or growth in certain markets if they materialize.
• Negative Sentiment: Large insider selling noted by data providers — recent public filings and data aggregators show substantial insider share sales over the past 6 months, which can amplify sell‑side pressure or signal near‑term positioning changes. QuiverQuant summary & insider activity
• Negative Sentiment: Product/segment items — notable declines or one‑time items (e.g., a material drop in spinal implants year/quarter comparisons and earlier goodwill/impairment charges) remain on the P&L and are potential longer‑term headwinds for parts of Orthopaedics. Stryker reports 2025 operating results and 2026 outlook

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.